Optimi Health Completes Third Commercial Psilocybin Export to Australia for Depression Treatment
OPTH sits 41% above its 52-week low of $3 on elevated volume (3.0× avg).
Summary
Optimi Health announced its third commercial export of 5mg psilocybin capsules to Australia for treatment-resistant depression, highlighting ongoing revenue and expanding reimbursement.
Key Events · Product Development and Regulatory · OPTH
-
Third Commercial Export to Australia
Optimi Health completed its third commercial shipment of 1,000 units of 5mg psilocybin capsules to Australia since launching in September 2025.
-
Treatment for Depression
The psilocybin capsules are prescribed in Australia for patients with treatment-resistant depression, a condition for which regulated access is available.
-
Expanding Reimbursement & Safety
The company notes expanding reimbursement coverage from both private and public insurers and reports no serious adverse events after more than two years of regulated commercial use in Australia.
-
GMP Production & Export
Capsules were produced at Optimi's GMP facility in Canada and exported under Health Canada authorization, contributing to recurring commercial revenue.
Analysis · OPTH · Life Sciences
This filing confirms Optimi Health's continued commercial progress in the regulated psychedelic medicine market. The third export of psilocybin capsules to Australia, coupled with expanding reimbursement coverage and a clean safety record, validates the company's strategy and regulatory navigation. It demonstrates ongoing revenue generation and strengthens its position as a commercial supplier in a nascent but growing industry.
At the time of this filing, OPTH was trading at $4.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23M. The 52-week trading range was $3.00 to $8.84. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.